Cargando…

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	CKD-Mdb
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025329/ https://www.ncbi.nlm.nih.gov/pubmed/32082556 http://dx.doi.org/10.1093/ckj/sfz034

Ejemplares similares

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
por: Bouma-de Krijger, Annet, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

WCN23-0120 MEDIUM AND LONG TERM ANTIBODY RESPONSE TO COVID-19 VACCINATION IN PATIENTS RECEIVING HEMODIALYSIS (HD) - A CROSS SECTIONAL STUDY
por: Cheema, S., et al.
Publicado: (2023)

WCN23-0981 RISK FACTORS FOR COVID-19 MORTALITY IN HEMODIALYSIS PATIENTS
por: TOMANOSKI, V., et al.
Publicado: (2023)

WCN23-0430 PREDICTORS FOR FAILURE REDUCTION OF HEMODIALYSIS FREQUENCY DURING THE PANDEMIC
por: Pattharanitima, P., et al.
Publicado: (2023)

WCN23-0345 EFFECTIVENESS OF COVID-19 VACCINE IN PATIENT UNDERGOING HEMODIALYSIS
por: FATIMAH, S., et al.
Publicado: (2023)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study
por: Rottembourg, Jacques, et al.
Publicado: (2019)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019)

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism
por: Sato, Tetsuhiko, et al.
Publicado: (2019)

Renal artery intervention utilizing carbon dioxide angiography
por: Sag, Alan A, et al.
Publicado: (2017)

Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy
por: Brown, Stephanie A, et al.
Publicado: (2017)

Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease
por: Hameed, Mohammed Awais, et al.
Publicado: (2017)

Patterns of progression of chronic kidney disease at later stages
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2018)

The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker
por: Canney, Mark, et al.
Publicado: (2018)

Frailty and chronic kidney disease: current evidence and continuing uncertainties
por: Nixon, Andrew C, et al.
Publicado: (2018)

A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records
por: Friberg, Leif, et al.
Publicado: (2018)

Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2017)

The metabolomic quest for a biomarker in chronic kidney disease
por: Davies, Robert
Publicado: (2018)

The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary
por: Pippias, Maria, et al.
Publicado: (2017)

Current trends in European renal epidemiology
por: Heaf, James
Publicado: (2017)

Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2017)

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis
por: Iyasere, Osasuyi, et al.
Publicado: (2018)

Clarifying the concept of chronic kidney disease for non-nephrologists
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Impact of a phone app on nephrology referral
por: Oliva-Damaso, Nestor, et al.
Publicado: (2018)

Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients
por: Lai, Silvia, et al.
Publicado: (2018)

Anticoagulant-related nephropathy: systematic review and meta-analysis
por: de Aquino Moura, Karolinny Borinelli, et al.
Publicado: (2019)

Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease
por: Hunt, Taylor V, et al.
Publicado: (2018)

Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1
por: Barbieri, Diego, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f3g1ds0g2bah29ivaina62m6sj